Crossject SA
PAR:ALCJ
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Crossject SA
PAR:ALCJ
|
103.1m EUR |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.9T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.6B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
109.6B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.8B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
3.9B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Crossject SA
Glance View
Crossject SA manufactures and markets needle-free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The firm has industrial partnerships with Hirtenberger and Recipharm.
